Tags » Adrenocortical Carcinoma

ArQule Announces Data Presentations with ARQ 087, Inhibitor of FGFR, at AACR

WOBURN, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq:ARQL) today announced that data with ARQ 087, a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor, will be presented today at the 2015 Annual Meeting of the American Association for Cancer Research (AACR). 315 more words

Preclinical & Clinical

Tekmira Announces Completion of Underwritten Public Offering of Common Shares

VANCOUVER, British Columbia, March 25, 2015 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has completed its previously announced underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses. 460 more words

Hepatocellular Carcinoma

Tekmira Announces Pricing of Underwritten Public Offering of Common Shares

VANCOUVER, British Columbia, March 20, 2015 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has priced an underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses. 484 more words

Hepatocellular Carcinoma

Tekmira Strengthens Senior Leadership Team With Key Executive Appointments in Corporate Affairs, Chemistry and Biology

VANCOUVER, British Columbia, March 18, 2015 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced three executive appointments: Adam Cutler has been appointed Senior Vice President, Corporate Affairs; Dr. 778 more words

Management & Board Appointments

Tekmira Provides Corporate Update and Announces Year-End 2014 Results

VANCOUVER, British Columbia, March 12, 2015 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced its 2014 audited financial results and provided a corporate update. 1,854 more words

Preclinical & Clinical

Atterocor Announces Data Presentations at ENDO 2015

ANN ARBOR, Mich.–(BUSINESS WIRE)–Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced three poster presentations on ATR-101 at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo, being held Mar. 525 more words

Preclinical & Clinical

Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma

VANCOUVER, British Columbia, Dec. 31, 2014 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided a status update on the Phase I/II clinical study in patients with advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) and Adrenocortical Carcinoma (ACC). 781 more words

Preclinical & Clinical